Bhaskar Roy, MBBS, MHS
Associate Professor of NeurologyCards
About
Titles
Associate Professor of Neurology
Director of the Muscular Dystrophy Association adult care clinic, Neurology; Medical Director of the Electrodiagnostic Laboratory, Yale Medicine
Positions outside Yale
Co-Chair of the IBM scientific interest group from IMACS, IMACS, IMACS
Biography
Dr Bhaskar Roy is a specialist in neuromuscular disorders. His clinical areas of expertise includes muscular dystrophies, inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis), autoimmune neuromuscular disorders, including inflammatory neuropathies. He did his neurology residency from the University of Connecticut and completed his fellowship from the Beth Israel Deaconess Medical Center, Harvard Medical School.
He is board certified in neurology (2016) and neuromuscular medicine (2018) by the American Board of Psychiatry and Neurology (ABPN) and in electrodiagnostic medicine (2018), and in Neuromuscular Ultrasound (2020) by the American Board of Electrodiagnostic Medicine (ABEM).
Appointments
Neurology
Associate Professor on TermPrimary
Other Departments & Organizations
- Bhaskar Roy Lab
- Center for Neuroepidemiology and Clinical Neurological Research
- IBM Registry
- Myasthenia Gravis Program
- Neurology
- Neuromuscular Medicine
- Nowak Lab
- O'Connor Lab
- Yale Medicine
Education & Training
- MHS
- Yale University School of Medicine (2020)
- Neuromuscular Medicine Fellow
- Beth Israel Deaconess Medical Center (2017)
- Resident Physician
- University of Connecticut (2016)
- Post Doctoral Research Fellow
- Brigham and Women's Hospital, Harvard Medical School (2012)
- MBioMedSci
- Indian Institution of Technology, Masters in Medical Science and Technology (MMST) (2011)
- MBBS
- Nilratan Sircar Medical College and Hospital (2008)
Research
Publications
2024
Decoding the molecular script of 2′-O-ribomethylation: Implications across CNS disorders
Verma A, Roy B, Dwivedi Y. Decoding the molecular script of 2′-O-ribomethylation: Implications across CNS disorders. Heliyon 2024, 10: e39036. PMID: 39524798, PMCID: PMC11550049, DOI: 10.1016/j.heliyon.2024.e39036.Peer-Reviewed Original ResearchRibosomal RNARibosome functionRibosomal RNA structuresPeptidyl transferase centerPost-transcriptional modificationsDefective ribosome biogenesisRibosome biogenesisRibosome integrityRNA modificationsRegulatory networksTranslational efficiencyDecoding siteImpaired mRNA translationMRNA translationBase modificationsPathophysiology of CNS disordersCNS disordersRNA integrityProtein synthesisRibosomal dysfunctionRNANeurodegenerative diseasesDisease pathologySpectrum of CNS disordersPrecision medicineCirculating long noncoding RNA: New frontiers in biomarker research for mood disorders
Roy B, Verma A, Hulwi E, Dwivedi Y. Circulating long noncoding RNA: New frontiers in biomarker research for mood disorders. 2024, 1-13. DOI: 10.61373/gp024i.0046.Peer-Reviewed Original ResearchMood disordersPathophysiology of mood disordersContext of mood disordersComplex psychiatric disorderSample of individualsDisease-specific contributionBipolar depressionPsychiatric disordersPredicting treatment responseMoodDisordersMental conditionTreatment responseBlood samples of individualsInvolvement of lncRNAsLong noncoding RNAsPeripheral blood samplesLncRNA researchLncRNAsMDDCognitionDepressionClinical studiesNoncoding RNAsIncreasing evidenceProteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003)
Roy B, Habiabadi F, O’Connor K, Nowak R, Kaminski H. Proteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205944.Peer-Reviewed Original ResearchTrial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004)
Roy B, Nowak R. Trial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205956.Peer-Reviewed Original Research
2023
Leg MRI as a Complementary Diagnostic Tool in the Assessment of Foot Drop
Torabi T, Zubair A, Nowak R, Tseng B, Haims A, Roy B. Leg MRI as a Complementary Diagnostic Tool in the Assessment of Foot Drop. Journal Of Clinical Neuromuscular Disease 2023, 25: 57-58. PMID: 37611274, DOI: 10.1097/cnd.0000000000000433.Peer-Reviewed Original ResearchPlasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.Peer-Reviewed Original ResearchConceptsNeuro-immunological diseaseIntravenous immunoglobulinAutoimmune neurological disordersAutoimmune neuromuscular disorderAdult patientsElderly patientsNeurological disordersNeuromuscular disordersChronic inflammatory demyelinating polyradiculoneuropathyNational Inpatient Sample databaseNational Inpatient Sample datasetInflammatory demyelinating polyradiculoneuropathySafe therapeutic choiceRetrospective chart reviewAppropriate clinical settingSide effect profileDemyelinating polyradiculoneuropathyIVIG useChart reviewYounger patientsMyasthenia gravisEffect profileMedical historyPrimary diagnosisTherapeutic choiceTherapeutic developments for valosin-containing protein mediated multisystem proteinopathy
Boock V, Roy B, Pfeffer G, Kimonis V. Therapeutic developments for valosin-containing protein mediated multisystem proteinopathy. Current Opinion In Neurology 2023, 36: 432-440. PMID: 37678339, DOI: 10.1097/wco.0000000000001184.Peer-Reviewed Original ResearchConceptsInclusion body myopathyPotential therapeutic targetValosin-containing proteinPaget's diseasePreclinical modelsTherapeutic approachesPotential therapyControl trialRare diseaseTherapeutic targetBody myopathyVivo modelFrontotemporal dementiaVCP mutationsMultisystem proteinopathyPathway involvementDiseaseTherapyMitochondrial dysfunctionTherapeutic developmentGene therapyMissense mutationsFunction activityATPase activityRCTsThe Impact of COVID-19 on Families With Pediatric Muscular Dystrophy Patients
Zubair A, Scharer K, Lembeck P, Ionita C, Roy B. The Impact of COVID-19 on Families With Pediatric Muscular Dystrophy Patients. Cureus 2023, 15: e41138. PMID: 37519528, PMCID: PMC10386847, DOI: 10.7759/cureus.41138.Peer-Reviewed Original ResearchPediatric patientsCOVID-19 pandemicMuscular dystrophyCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicParents/caregiversMuscular dystrophy patientsChart reviewCaregiver burdenHome ordersPerson visitsLong-term effectsNeuromuscular conditionsProvider careNeuromuscular disordersPatientsPsychosocial impactDystrophy patientsSchool closuresNeuromuscular disabilitiesMajority of familiesHealthcare servicesSocial distancing measuresCOVID-19Daily activitiesThe Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties
Jiang R, Roy B, Wu Q, Mohanty S, Nowak R, Shaw A, Kleinstein S, O’Connor K. The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties. ImmunoHorizons 2023, 7: 310-322. PMID: 37171806, PMCID: PMC10579972, DOI: 10.4049/immunohorizons.2200078.Peer-Reviewed Original ResearchConceptsInclusion body myositisMemory B cellsCell infiltrateBody myositisB cellsIBM muscle biopsiesB-cell infiltratesPlasma cell infiltrateClass-switched IgGMuscle tissueAdaptive immune receptor repertoire sequencingHumoral responseHealthy controlsIgA isotypePlasma cellsCell repertoireMuscle biopsyInfiltratesDegenerative disordersDisease pathologyRepertoire sequencingSkeletal muscleDermatomyositisPolymyositisMyositisImaging biomarkers in the idiopathic inflammatory myopathies
Zubair A, Salam S, Dimachkie M, Machado P, Roy B. Imaging biomarkers in the idiopathic inflammatory myopathies. Frontiers In Neurology 2023, 14: 1146015. PMID: 37181575, PMCID: PMC10166883, DOI: 10.3389/fneur.2023.1146015.Peer-Reviewed Original ResearchIdiopathic inflammatory myopathiesManagement of IIMMagnetic resonance imagingElectrical impedance myographyPositron emission tomographyInflammatory myopathiesMuscle ultrasoundExtra-muscular manifestationsMuscle strength testingQuality of lifeObjective assessmentMuscle inflammationPatient managementTreatment responseBetter objective assessmentMuscle damageMuscle healthResonance imagingEmission tomographyClinical settingMuscle diseaseBiomarkersImpedance myographyMyopathyFurther validation
Clinical Trials
Current Trials
Efficacy and Safety of ABC008 in Inclusion Body Myositis
HIC ID2000034270RolePrincipal InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
HIC ID2000031341RoleSub InvestigatorPrimary Completion Date02/21/2024Recruiting ParticipantsGenderBothAge18+ yearsMyasthenia Gravis Inebilizumab Trial (MINT)
HIC ID2000029503RoleSub InvestigatorPrimary Completion Date06/30/2023Recruiting ParticipantsGenderBothAge18+ yearsRegistry of Patients With Generalized Myasthenia Gravis Who Have Ever Been Treated With C5 Inhibition Therapies
HIC ID2000026785REGRoleSub InvestigatorPrimary Completion Date12/31/2021Recruiting ParticipantsExploring the relationship between electrical impedance myography (EIM) parameters with magnetic resonance imaging, and quantitative ultrasound parameters in Inclusion Body Myositis
HIC ID2000029791RolePrincipal InvestigatorPrimary Completion Date01/31/2024Recruiting ParticipantsGenderBothAge45 years - 90 years
Clinical Care
Overview
Bhaskar Roy, MBBS, (a medical degree awarded in several countries outside of the U.S.), is a neurologist who specializes in neuromuscular disorders and has deep expertise in using electromyography (EMG), a medical test that measures electrical activity in a patient’s nerves and muscles, to diagnose diseases. Dr. Roy cares for patients with muscular dystrophies, inflammatory myopathies (myositis), neuropathy, and autoimmune neuromuscular disorders. He is interested in rare and complex neuromuscular disorders, including inclusion body myositis (IBM) and other hereditary muscle diseases.
“Neuromuscular disorders are complex,” Dr. Roy says. “The challenge of diagnosis is what drew my attention to this field. These patients are a unique group of people who really need help. Some of them have gone undiagnosed for a long time.” Specialized neuromuscular care can help ensure that therapy is given as early as possible when applicable, he adds.
In addition to EMG, Dr. Roy is also trained in using neuromuscular ultrasound. “This is a relatively newer mode of technology that allows a physician to see some of the nerves and muscle tissue.”
Neuromuscular medicine has advanced rapidly in recent years and new drugs are available for patients with diseases that were previously not treatable, Dr. Roy says. His research on biomarkers—which are measurable markers that indicate a status of disease or health in the body—could help neurologists better understand a patient’s response to a treatment. In his studies, Dr. Roy uses electrical impedance myography (EIM), a painless test that assesses muscle health in a noninvasive way.
Dr. Roy is an assistant professor of neurology at the Yale School of Medicine.
Clinical Specialties
Fact Sheets
Muscular Dystrophy
Learn More on Yale MedicinePeripheral Neuropathy
Learn More on Yale MedicineNeuropathy
Learn More on Yale MedicineMyasthenia Gravis
Learn More on Yale Medicine
Board Certifications
Neuromuscular Medicine
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 2018
Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 2016